TY - JOUR
T1 - Noninvasive Molecular Imaging of the Enhanced Permeability and Retention Effect by 64Cu-Liposomes
T2 - In vivo Correlations with 68Ga-RGD, Fluid Pressure, Diffusivity and 18F-FDG
AU - Børresen, Betina
AU - Hansen, Anders Elias
AU - Fliedner, Frederikke Petrine
AU - Henriksen, Jonas Rosager
AU - Elema, Dennis Ringkjøbing
AU - Brandt-Larsen, Malene
AU - Kristensen, Lotte Kellemann
AU - Kristensen, Annemarie Thuri
AU - Andresen, Thomas Lars
AU - Kjær, Andreas
N1 - © 2020 Børresen et al.
PY - 2020
Y1 - 2020
N2 - Background: The accumulation of liposome encapsulated chemotherapy in solid cancers is dependent on the presence of the enhanced permeability and retention (EPR) effect. Positron emission tomography (PET) imaging with a liposome encapsulated radioisotope, such as liposome encapsulated Cu-64 (64Cu-liposome) may help to identify tumors with high liposome accumulation, and thereby stratify patients based on expected benefit from liposomal chemotherapy. However, intravenous administration of liposomes without a cytotoxic content is complicated by the accelerated blood clearance (ABC) phenomenon for succeeding therapeutic liposome dosing. Alternative markers for assessing the tumor's EPR level are therefore warranted.Materials and Methods: To increase our understanding of EPR variations and to ultimately identify an alternative marker for the EPR effect, we investigated the correlation between 64Cu-liposome PET/CT (EPR effect) and 68Ga-RGD PET/CT (neoangiogenesis), 18F-FDG PET/CT (glycolysis), diffusion-weighted MRI (diffusivity) and interstitial fluid pressure in two experimental cancer models (CT26 and COLO 205).Results: 64Cu-liposome and 68Ga-RGD SUVmax displayed a significant moderate correlation, however, none of the other parameters evaluated displayed significant correlations. These results indicate that differences in neoangiogenesis may explain some EPR variability, however, as correlations were only moderate and not observed for SUVmean, 68Ga-RGD is probably insufficient to serve as a stand-alone surrogate marker for quantifying the EPR effect and stratifying patients.
AB - Background: The accumulation of liposome encapsulated chemotherapy in solid cancers is dependent on the presence of the enhanced permeability and retention (EPR) effect. Positron emission tomography (PET) imaging with a liposome encapsulated radioisotope, such as liposome encapsulated Cu-64 (64Cu-liposome) may help to identify tumors with high liposome accumulation, and thereby stratify patients based on expected benefit from liposomal chemotherapy. However, intravenous administration of liposomes without a cytotoxic content is complicated by the accelerated blood clearance (ABC) phenomenon for succeeding therapeutic liposome dosing. Alternative markers for assessing the tumor's EPR level are therefore warranted.Materials and Methods: To increase our understanding of EPR variations and to ultimately identify an alternative marker for the EPR effect, we investigated the correlation between 64Cu-liposome PET/CT (EPR effect) and 68Ga-RGD PET/CT (neoangiogenesis), 18F-FDG PET/CT (glycolysis), diffusion-weighted MRI (diffusivity) and interstitial fluid pressure in two experimental cancer models (CT26 and COLO 205).Results: 64Cu-liposome and 68Ga-RGD SUVmax displayed a significant moderate correlation, however, none of the other parameters evaluated displayed significant correlations. These results indicate that differences in neoangiogenesis may explain some EPR variability, however, as correlations were only moderate and not observed for SUVmean, 68Ga-RGD is probably insufficient to serve as a stand-alone surrogate marker for quantifying the EPR effect and stratifying patients.
KW - Animals
KW - Cell Line, Tumor
KW - Colorectal Neoplasms/diagnostic imaging
KW - Contrast Media
KW - Copper Radioisotopes/pharmacokinetics
KW - Diffusion
KW - Female
KW - Fluorodeoxyglucose F18/pharmacokinetics
KW - Gallium Radioisotopes/pharmacokinetics
KW - Humans
KW - Liposomes/administration & dosage
KW - Magnetic Resonance Imaging/methods
KW - Mice, Inbred BALB C
KW - Molecular Imaging/methods
KW - Neoplasms/blood supply
KW - Neovascularization, Pathologic/diagnostic imaging
KW - Oligopeptides/pharmacokinetics
KW - Permeability
KW - Positron Emission Tomography Computed Tomography/methods
KW - Pressure
KW - Radiopharmaceuticals/pharmacokinetics
KW - Tumor Microenvironment
KW - Xenograft Model Antitumor Assays
U2 - 10.2147/IJN.S239172
DO - 10.2147/IJN.S239172
M3 - Journal article
C2 - 33173294
VL - 15
SP - 8571
EP - 8581
JO - International Journal of Nanomedicine
JF - International Journal of Nanomedicine
SN - 1176-9114
ER -